• Wockhardt (India)

• Ranbaxy Laboratories (India)

• elbion (Germany)

Featured Target Pipeline:

• PDE-4 Inhibitors

• Actice development programs for biogenerics;
• Focus on infectious disease R&D with small molecule programs;
• Several gyrase inhibitors in preclinical and clinical stages;
• Presentation forms are topical, oral and iv

• India 's largest integrated pharmaceutical company with international reach;
• Generic products and proprietary drug discovery and development;
• Focus on small molecule products;
• Predominantly early stage pipeline;
• Therapeutic focus on metabolism, infectious, genitourinary and pulmonary

• management buy-out from from AWD Pharma in 2002;
• lead program of PDE-4 inhibitor partnered with GlaxoSmithKline;
• further phase II programs in anxiety disorders and overactive bladder;
• plans to commence clinical testing with fourth compound in 2006;

• Proprietary vaccine technology of DNA plasmid boost followed by prime with non-replicating MVA vector;
• Phase II projects in HBV and melanoma;
• Follow-on projects in preclinical stage;
• HIV application targeting multiple antigen and epitopes